Glycoprotein, E.g., Mucins, Proteoglycans, Etc. Patents (Class 530/395)
  • Patent number: 9952203
    Abstract: The present invention relates to a new binder molecule useful e.g. as an immune suppressor. In particular, it has been recognized that the UL11 protein of human the cytomegalovirus, binds to the CD45 molecule, potentially altering the immune system of an individual. In addition, the present invention relates to binder molecules, in particular, fusion molecules containing the CD45 binding domain of the UL11 protein in combination with a second molecule of interest for delivery of said molecule to cells expressing the CD45 molecule. Moreover, the present invention relates to pharmaceutical compositions comprising the UL11 protein of human cytomegalovirus, or derivatives or homologs thereof, or a nucleic acid sequence encoding the same.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: April 24, 2018
    Assignee: Medizinische Hochschule Hannover
    Inventors: Penelope Kay-Fedorov, Martin Messerle, Thomas F. Schulz, Lars Steinbrück, Ildar Gabaev
  • Patent number: 9931392
    Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: April 3, 2018
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
  • Patent number: 9808417
    Abstract: Disclosed is a method of treating skin in need thereof, the method comprising topically applying to the skin a composition comprising an effective amount of an ethanolic or a butanolic extract from the leaf and stem of Docynia delavajy, wherein the composition reduces oxidation in the skin, reduces tumor necrosis factor-alpha (TNF-?) in the skin, or reduces metalloprotease-1 (MMP-1) activity in the skin.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: November 7, 2017
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, Michelle Hines
  • Patent number: 9624470
    Abstract: This invention relates to hematopoietic precursors derived from human embryonic stem cells. In the culture of differentiated cells from human ES cells, the fully committed hematopoietic precursors are CD34+ and CD43+ but not CD45+. If the cells are cultured until they express CD45, then the cells lose the ability to produce differentiated cells of the lymphoid lineages.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: April 18, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Igor I. Slukvin, Maksym A. Vodyanyk, James A. Thomson
  • Patent number: 9498427
    Abstract: Disclosed are compositions that include Docynia delavajy extract, Elaeagnus lanceolatus extract, or a combination of such extracts.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: November 22, 2016
    Assignee: MARY KAY INC.
    Inventors: Tiffany Florence, Michelle Hines
  • Patent number: 9499602
    Abstract: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 22, 2016
    Inventors: Yvonne Paterson, Paulo MaCiag
  • Patent number: 9416173
    Abstract: Several new peptides have been developed that show effectiveness as vaccines against candidiasis and other fungal diseases. A new conjugate vaccine of a ?-mannotriose linked to a fungal peptide linked to tetanus toxin has been shown to be effective as a vaccine with or without use of an adjuvant. In addition, a monoclonal antibody has been identified that offers protection from a Candida infection.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: August 16, 2016
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Hong Xin, Jim E. Cutler
  • Patent number: 9383352
    Abstract: Disclosed herein are methods and tests for diagnosing and/or monitoring a metabolic condition such as diabetes in a subject, wherein the methods and tests measure salivary glycoproteins. Some of the methods are based on the oxidation of glycoproteins in a sample from the subject, such as saliva or urine, for example using sodium metaperiodate, and then detecting the aldehydes generated during oxidation using a chemical detection method. Also disclosed are kits and lateral flow devices for detecting glycoproteins in a saliva sample.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: July 5, 2016
    Assignee: Diabetomics, Inc.
    Inventors: Srinivasa R. Nagalla, Eric S. Bean
  • Patent number: 9260507
    Abstract: A peptide is provided with a defined sequence present in the alpha3 chain of the LG4 globule of laminin 332 (laminin 5), and peptides with sequences homologous to the peptide with the defined sequence capable of binding to the syndecan-1 receptor. Pharmaceutical or cosmetic compositions containing the peptide are provided. The peptide is used in the area of tissue healing and regeneration or as an adjuvant in culture media intended for epidermal or epithelial reconstruction. The synthetic peptide comprises the sequence KKLRIKSKEK (SEQ ID NO: 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: February 16, 2016
    Assignees: Symatese, Centre National De La Recherche Scientifique, Universite Claude Bernard Lyon I
    Inventor: Patricia Rousselle
  • Patent number: 9260535
    Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: February 16, 2016
    Assignee: NutriLeads B.V.
    Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
  • Patent number: 9234895
    Abstract: The present invention relates generally to methods for identifying organ-specific secreted proteins and for identifying organ-specific molecular blood fingerprints therefrom. As such, the present invention provides compositions comprising such proteins, detection reagents for detecting such proteins, and panels, and arrays for determining organ-specific molecular blood fingerprints.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: January 12, 2016
    Assignee: Institute for Systems Biology
    Inventors: Leroy Hood, Biaoyang Lin
  • Patent number: 9216220
    Abstract: Provided herein are systems, methods, and compositions for polymer nanoparticles and polymer magnetic nanoparticles. More particularly, the polymer nanoparticles and polymer magnetic nanoparticles are temperature sensitive and responsive to a first temperature.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: December 22, 2015
    Inventors: Kytai T. Nguyen, Maham Rahimi, Soujanya Kona, Arthur H. Lin
  • Patent number: 9192593
    Abstract: An amino-acid containing composition for inhibiting accumulation of fat, containing leucine in an amount of 33 to 67% by weight and threonine in an amount of 33 to 67% by weight, in terms of free amino acids thereof, based on whole amino acids.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: November 24, 2015
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yuri Hirabayashi, Hitoshi Murakami, Hisamine Kobayashi
  • Patent number: 9095600
    Abstract: The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction. The present invention provides a preventive and/or therapeutic drug for myocardial infarction or myocardial ischemia-reperfusion injury, the drug containing a lipid membrane structure retaining adenosine.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: August 4, 2015
    Inventors: Tetsuo Minamino, Masafumi Kitakaze, Masatsugu Hori, Hiroyuki Takahama, Hiroshi Kikuchi, Kouichi Hashimoto, Hideo Kobayashi, Ayako Iijima, Daigo Asano
  • Patent number: 9068001
    Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: June 30, 2015
    Assignees: Selexys Pharmaceuticals, Oklahoma Medical Research Foundation
    Inventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
  • Patent number: 9040478
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 26, 2015
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 9040020
    Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 26, 2015
    Assignee: Technische Universitaet Muenchen
    Inventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
  • Publication number: 20150139904
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: University of Miami
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
  • Publication number: 20150141626
    Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
    Type: Application
    Filed: January 2, 2015
    Publication date: May 21, 2015
    Inventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Publication number: 20150133528
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 14, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20150133363
    Abstract: The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.
    Type: Application
    Filed: December 18, 2014
    Publication date: May 14, 2015
    Inventors: Jean-Luc BATTINI, Nicolas MANEL, Felix KIM, Sandrina KINET, Naomi TAYLOR, Marc SITBON
  • Patent number: 9029506
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: May 12, 2015
    Assignees: aTyr Pharma, Inc., Pangn Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Patent number: 9024110
    Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: May 5, 2015
    Inventors: Zhang Yang, Damian Paul Drew, Emma Adhiambo Arigi, Peter Ulvskov, Steven B. Levery, Eric Bennett, Henrik Clausen, Brent Larsen Petersen
  • Publication number: 20150119558
    Abstract: The present invention provides modified cells for producing proteins with modified glycosylation patterns. Proteins produced in such cells, and the use of such proteins in medicine, and particularly in the treatment of cancer, is also provided.
    Type: Application
    Filed: January 18, 2013
    Publication date: April 30, 2015
    Inventor: Zhiwei Song
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150110829
    Abstract: Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Che-Hung Robert Lee, Valerian B. Pinto
  • Publication number: 20150112047
    Abstract: Disclosed is a bifunctional adapter molecule comprising two binding moieties A and B, the adapter molecule being capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag, wherein the binding moiety A comprises at least two chelating groups K, wherein each chelating group is capable of binding to a transition metal ion, thereby rendering moiety A capable of binding to an oligohistidine affinity tag, and the binding moiety B is an affinity tag other than an oligohistidine tag.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Inventor: Thomas SCHMIDT
  • Publication number: 20150112022
    Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 23, 2015
    Inventors: Ashutosh Chilkoti, Felipe Garcia Quiroz, Miriam Amiram
  • Publication number: 20150110826
    Abstract: The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Anne-Cecile V. BAYNE, James Casey LIPPMEIER, Kirk Emil APT, Ross Eric ZIRKLE
  • Publication number: 20150104816
    Abstract: A marker for detecting pancreatic cancer, said marker comprising a glycoprotein C4BPA or PIGR, whereby a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and thus specifically diagnosed. Also, the marker is usable in monitoring the postoperative prognosis of a pancreatic cancer patient. When the aforesaid marker is used in combination with another pancreatic cancer marker such as CA19-9, furthermore, a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and diagnosed more specifically.
    Type: Application
    Filed: April 1, 2013
    Publication date: April 16, 2015
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Kenta Noda, Toshihide Miura, Humio Nomura, Kazuyuki Sogawa, Mamoru Sato, Hideyuki Yoshitomi, Masaru Miyazaki
  • Publication number: 20150105325
    Abstract: Disclosed are pharmaceutical and synergistic compositions comprising human recombination alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 16, 2015
    Inventors: Igor Dudich, Lydia Semenkova, Igor Dudich, Eduard Tatulov
  • Publication number: 20150104479
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 16, 2015
    Applicant: NOVARTIS AG
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Publication number: 20150098955
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: October 10, 2012
    Publication date: April 9, 2015
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • Publication number: 20150093401
    Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.
    Type: Application
    Filed: April 11, 2013
    Publication date: April 2, 2015
    Applicant: UCL BUSINESS PLC
    Inventors: Martin Pulé, Brain Phillip
  • Publication number: 20150093331
    Abstract: The present invention relates to biomarkers, methods and assay kits for the identification, monitoring and treatment of breast cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 2, 2015
    Applicant: OncoLock Co., Ltd.
    Inventor: Yeou-Guang Tsay
  • Publication number: 20150086584
    Abstract: Compositions comprising aptamers or other binding ligands provide immune cell regulatory signals and specificity to secreted cell molecules at in vivo foci of immune activity.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicant: University of Miami
    Inventors: Eli Gilboa, Randall Brennerman, Brett Schrand
  • Publication number: 20150087815
    Abstract: The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the compositions described herein.
    Type: Application
    Filed: December 4, 2014
    Publication date: March 26, 2015
    Inventors: Syed Saleem AHMED, John Joseph BUCKLEY, III, Lavinia Marina LEWIS, Brandi Rae OSBORNE, Sandipan SINHA, Jennifer Marie THORN, Ferhana ZAMAN
  • Publication number: 20150086580
    Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
  • Publication number: 20150079658
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: J Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Publication number: 20150079612
    Abstract: The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.
    Type: Application
    Filed: November 30, 2012
    Publication date: March 19, 2015
    Inventors: Paul Q. Hu, Xiaofen Huang, Reid W. Von Borstel
  • Publication number: 20150079129
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Carine CAPIAU, Marguerite DESCHAMPS, Pierre Michel DESMONS, Craig Antony Joseph LAFERRIERE, Jan POOLMAN, Jean-Paul PRIEELS
  • Patent number: 8980280
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: March 17, 2015
    Assignees: Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-Sud
    Inventors: Herve Poulet, Thierry Heidmann
  • Patent number: 8980268
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: March 17, 2015
    Assignee: Regeneron Pharamceuticals, Inc.
    Inventors: Israel Lowy, Gavin Thurston, Christopher Daly
  • Publication number: 20150071954
    Abstract: The present invention relates to a gp41 trivalent peptide mimetic having three gp41 N-peptides on a chemical scaffold which conformationally constrains the N-peptides into a trimeric coiled-coil to mimic gp41 presentation. The present invention also relates to N-peptides having the entire HIV gp41 NH2-terminal heptad repeat region and which are capable of forming gp41 peptide mimetics. Such peptide mimetics of HIV-1 gp41 pre-hairpin intermediates can be utilized in a vaccine for the treatment or prevention of HIV-1 infection through eliciting neutralizing antibodies.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 12, 2015
    Inventors: Joseph G. Joyce, Chengwei Wu, Elizabeth A. Ottinger, Victor garsky
  • Patent number: 8969066
    Abstract: The present invention provides compositions and methods for producing flocculation moieties in photosynthetic organisms. The photosynthetic organisms are genetically modified to effect production, secretion, or both, of the flocculation moieties. Also provided are methods of flocculating organisms.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: March 3, 2015
    Assignee: Sapphire Energy, Inc.
    Inventors: Michael Mendez, Craig Behnke, Yan Poon, Philip Lee
  • Publication number: 20150057439
    Abstract: New methods for the refolding of recombinant granulocyte colony stimulating factor (G-CSF) from inclusion bodies are disclosed. The methods comprise two refolding steps. In particular, the methods comprise the solubilising of G-CSF with a solubilising agent, the oxidative refolding (first refolding step) of G-CSF in the presence of the solubilising agent and an oxidizing agent, the efficient removal of the solubilising agent, and a second refolding step to complete the folding of G-CSF in the absence of the solubilising agent. Various methods are described for the efficient removal of the solubilising agent from partially refolded G-CSF.
    Type: Application
    Filed: March 18, 2013
    Publication date: February 26, 2015
    Applicant: Richter Gedeon Nyrt.
    Inventors: Ferenc Felföldi, Andras Ballagi, János Bécsi
  • Patent number: 8962802
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 24, 2015
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Patent number: 8962811
    Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: February 24, 2015
    Assignee: Ohio University
    Inventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary Meyer
  • Publication number: 20150051149
    Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
    Type: Application
    Filed: October 31, 2012
    Publication date: February 19, 2015
    Inventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen